Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease
Authors
Keywords
-
Journal
HYPERTENSION
Volume 77, Issue 5, Pages 1442-1455
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-03-29
DOI
10.1161/hypertensionaha.121.17005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2020) Boris Bikbov et al. LANCET
- Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
- (2020) Meg J. Jardine et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- (2020) Jennifer E. Flythe et al. KIDNEY INTERNATIONAL
- Identifying new cellular mechanisms of mineralocorticoid receptor activation in the heart
- (2020) Morag J. Young et al. JOURNAL OF HUMAN HYPERTENSION
- SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
- (2020) Alexia Piperidou et al. JOURNAL OF HUMAN HYPERTENSION
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
- (2020) Adeera Levin et al. Clinical Journal of the American Society of Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
- (2020) David C Wheeler et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Effects of Canagliflozin in Patients with Baseline eGFR
- (2020) George Bakris et al. Clinical Journal of the American Society of Nephrology
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function
- (2020) David Z.I. Cherney et al. CIRCULATION
- Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
- (2020) John J.V. McMurray et al. CIRCULATION
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
- (2019) Pantelis Sarafidis et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial
- (2019) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Mineralocorticoid receptor antagonists in chronic kidney disease and albuminuria
- (2019) Pantelis A. Sarafidis et al. CURRENT PHARMACEUTICAL DESIGN
- The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward
- (2019) Patrick Rossignol et al. KIDNEY INTERNATIONAL
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
- (2019) Annabelle M. Warren et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection
- (2019) Charalampos Loutradis et al. Future Medicinal Chemistry
- Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- (2019) Andrew A. House et al. KIDNEY INTERNATIONAL
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
- (2019) Kitty J. Jager et al. KIDNEY INTERNATIONAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Blood Pressure Control on Long‐Term Risk of End‐Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease
- (2019) Elaine Ku et al. Journal of the American Heart Association
- The beneficial actions of SGLT-2 inhibitors beyond management of hyperglycemia
- (2019) Charalampos Loutradis et al. CURRENT MEDICINAL CHEMISTRY
- US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2019) Rajiv Saran et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
- (2019) Maria-Eleni Alexandrou et al. JOURNAL OF HYPERTENSION
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
- (2018) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report
- (2018) Matthew R. Weir et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
- (2018) Paresh Dandona et al. DIABETES CARE
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. JOURNAL OF HYPERTENSION
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypertension in dialysis patients
- (2017) Pantelis A. Sarafidis et al. JOURNAL OF HYPERTENSION
- Effects of Intensive BP Control in CKD
- (2017) Alfred K. Cheung et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The systemic nature of CKD
- (2017) Carmine Zoccali et al. Nature Reviews Nephrology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials
- (2017) Youxia Liu et al. BMC Nephrology
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis
- (2017) Yen-Chung Lin et al. PLoS One
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN JOURNAL OF HEART FAILURE
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- (2016) T. D. Filippatos et al. EXPERT OPINION ON PHARMACOTHERAPY
- Global cardiovascular protection in chronic kidney disease
- (2016) Gema Ruiz-Hurtado et al. Nature Reviews Cardiology
- Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis
- (2016) Hong-Jin Zhao et al. RENAL FAILURE
- Advances in treatment of hyperkalemia in chronic kidney disease
- (2015) Pantelis A Sarafidis et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues
- (2015) Panagiotis I. Georgianos et al. Journal of Clinical Hypertension
- Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study
- (2015) ChongTing Lin et al. Journal of Clinical Hypertension
- Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease
- (2015) Konstantinos P. Imprialos et al. JOURNAL OF HYPERTENSION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Intensive versus Standard Blood-Pressure Control
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
- (2013) Yoshihiro Matsumoto et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?
- (2013) Pantelis A. Sarafidis et al. KIDNEY INTERNATIONAL
- Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial
- (2013) K. Iseki et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients
- (2012) J.-M. Halimi DIABETES & METABOLISM
- Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression
- (2012) Pantelis A Sarafidis et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic kidney disease
- (2011) Andrew S Levey et al. LANCET
- Endothelin antagonism for diabetic nephropathy
- (2010) Pantelis A. Sarafidis et al. Nature Reviews Nephrology
- Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
- (2010) Lawrence J. Appel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Renin-Angiotensin System Blockers on Renal Outcomes and All-cause Mortality in Patients With Diabetic Nephropathy: An Updated Meta-analysis
- (2008) P. A. Sarafidis et al. AMERICAN JOURNAL OF HYPERTENSION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started